Multidisciplinary consensus recommendations from a European network for the diagnosis and practical management of patients with incontinentia pigmenti.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
24
11
2019
revised:
28
02
2020
accepted:
10
03
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Incontinentia pigmenti (IP) is a rare multisystemic X-linked dominant genetic disorder characterized by highly diagnostic skin lesions. The disease can be misdiagnosed in infants, and complications affecting the eyes and/or the brain can be severe. Our objective was to highlight the urgency of an appropriate diagnosis and management strategy, as soon as the first symptoms appear, and the need for a well-codified monitoring strategy for each child. An in-depth literature review using a large number of databases was conducted. The selection criteria for articles were literature review articles on the disease, case series and retrospective studies based on the disease, clinical studies (randomized or not) on treatment, articles discussing patient care and management (treatment, diagnosis, care pathways), and recommendations. The research period was from 2000 until 2018. A group of multidisciplinary experts in IP management was involved, issued from different healthcare providers of the European Network for Rare Skin Diseases (ERN-Skin). The final recommendations have been submitted to two patient representative associations and to a general practitioner and a neonatal specialist prior to their finalization. The diagnosis of IP must be promptly performed to detect potential extracutaneous manifestations, thus allowing the timely implementation of specific therapeutic and monitoring strategies. Eye involvement can be a therapeutic urgency, and central nervous system (CNS) involvement requires a very rigorous long-term follow-up. Assessments and patient support should take into account the possible co-occurrence of various symptoms (including motor, visual and cognitive symptoms).
Sections du résumé
BACKGROUND
BACKGROUND
Incontinentia pigmenti (IP) is a rare multisystemic X-linked dominant genetic disorder characterized by highly diagnostic skin lesions. The disease can be misdiagnosed in infants, and complications affecting the eyes and/or the brain can be severe. Our objective was to highlight the urgency of an appropriate diagnosis and management strategy, as soon as the first symptoms appear, and the need for a well-codified monitoring strategy for each child.
METHODS
METHODS
An in-depth literature review using a large number of databases was conducted. The selection criteria for articles were literature review articles on the disease, case series and retrospective studies based on the disease, clinical studies (randomized or not) on treatment, articles discussing patient care and management (treatment, diagnosis, care pathways), and recommendations. The research period was from 2000 until 2018. A group of multidisciplinary experts in IP management was involved, issued from different healthcare providers of the European Network for Rare Skin Diseases (ERN-Skin). The final recommendations have been submitted to two patient representative associations and to a general practitioner and a neonatal specialist prior to their finalization.
RESULTS AND CONCLUSION
CONCLUSIONS
The diagnosis of IP must be promptly performed to detect potential extracutaneous manifestations, thus allowing the timely implementation of specific therapeutic and monitoring strategies. Eye involvement can be a therapeutic urgency, and central nervous system (CNS) involvement requires a very rigorous long-term follow-up. Assessments and patient support should take into account the possible co-occurrence of various symptoms (including motor, visual and cognitive symptoms).
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1424Subventions
Organisme : Fimarad: French national network for rare skin diseases.
Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Smahi A, Courtois G, Vabres P et al. Genomic rearrangement in NEMO impairs NF-kappa B activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000; 405:466-472.
Fusco F, Paciolla M, Conte MI et al. Incontinentia pigmenti: report on data from 2000 to 2013. Orphanet J Rare Dis 2014; 9: 93.
Hadj-Rabia S, Froidevaux D, Bodak N et al. Clinical study of 40 cases of incontinentia pigmenti. Arch Dermatol 2003; 139: 1163-1170.
Minic S, Trpinac D Obradovic M. Incontinentia pigmenti diagnostic criteria update. Clin Genet. 2014; 85:536-542.
Scheuerle AE. Incontinentia pigmenti. Orphanet J Rare Dis [Internet]. [WWW document] 2013. URL htpps://www.orpha.net/consor/cgi-bin/OC_ (last accessed: 04 January 2013).
Fusco F, Fimiani G, Tadini G, Michele D, Ursini MV. Clinical diagnosis of incontinentia pigmenti in a cohort of male patients. J Am Acad Dermatol. 2007; 56: 264-267.
Fraitag S, Rimella A, de Prost Y, Brousse N, Hadj-Rabia S, Bodemer C. Skin biopsy is helpful for the diagnosis of incontinentia pigmenti at late stage (IV): a series of 26 cutaneous biopsies. J Cutan Pathol. 2009; 36: 966-971.
Bodak N, Hadj-Rabia S, Hamel-Teillac D, de Prost Y, Bodemer C. Late recurrence of inflammatory first-stage lesions in incontinentia pigmenti: an unusual phenomenon and a fascinating pathologic mechanism. Arch Dermatol 2003; 139: 201-204.
Dupati A, Egbers RG, Helfrich YR. A case of incontinentia pigmenti reactivation after 12-month immunizations. JAAD Case Rep 2015; 1: 351-352.
Ferneiny M, Hadj-Rabia S, Regnier S et al. Unique subungueal keratoacanthoma revealing incontinentia pigmenti. J Eur Acad Dermatol Venereol 2016; 30: 1401-1403.
Poziomczyk CS, Recuero JK, Bringhenti L et al. Incontinentia pigmenti. An Bras Dermatol 2014; 89: 26-36.
Hadj-Rabia S, Rimella A, Smahi A et al. Clinical and histologic features of incontinentia pigmenti in adults with nuclear factor-κB essential modulator gene mutations. J Am Acad Dermatol 2011; 64: 508-515.
Minic S, Obradovic M, Kovacevic I, Trpinac D. Ocular anomalies in incontinentia pigmenti: literature review and meta-analysis. Srp Arh Celok Lek 2010; 138: 408-413.
Rosenthal AC, Folster-Holst R. [Incontinentia pigmenti: Herpes simplex infection as an important differential diagnosis in the neonatal period]. Der Hautarzt 2017; 68: 149-152.
O'Doherty M, Mc Creery K, Green AJ, Tuwir I, Brosnahan D. Incontinentia pigmenti-ophthalmological observation of a series of cases and review of the literature. Br J Ophthalmol 2011; 95: 11-16.
Wolf NI, Kramer N, Harting I et al. Diffuse cortical necrosis in a neonate with incontinentia pigmenti and an encephalitis-like presentation. AJNR Am J Neuroradiol 2005; 26: 1580-1582.
Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, Martinez V. [Incontinentia pigmenti: clinical and neuroimaging findings in a series of 12 patients]. Neurologia 2006; 21: 239-248.
Meuwissen ME, Mancini GM. Neurological findings in incontinentia pigmenti; a review. Eur J Med Genet 2012; 55: 323-331. Review.
Bodemer C. Incontinentia pigmenti and hypomelanosis of Ito. Handb Clin Neurol 2013; 111: 341-347.
Minic S, Trpinac D, Obradovic M. Systematic review of central nervous system anomalies in incontinentia pigmenti. Orphanet J Rare Dis 2013; 8: 25.
Pizzamiglio MR, Piccardi L, Bianchini F et al. Incontinentia pigmenti: learning disabilities are a fundamental hallmark of the disease. PLoS ONE 2014; 9: e87771.
Pizzamiglio MR, Piccardi L, Bianchini F et al. Cognitive-behavioural phenotype in a group of girls from 1.2 to 12 years old with the Incontinentia Pigmenti syndrome: Recommendations for clinical management. Appl Neuropsychol Child 2017; 6: 327-334.
Kibbi N, Totonchy M, Suozzi KC, Ko CJ, Odell ID. A case of subungual tumors of incontinentia pigmenti: a rare manifestation and association with bipolar disease. JAAD Case Rep 2018; 4: 737-741.
Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007; 61: 3-19.
Wong EH, So HC, Li M et al. Common variants on Xq28 conferring risk of schizophrenia in Han Chinese. Schizophr Bull 2014; 40: 777-786.
Firouzabadi SG, Kariminejad R, Vameghi R et al. Copy number variants in patients with autism and additional clinical features: report of VIPR2 duplication and a novel microduplication syndrome. Mol Neurobiol 2017; 54: 7019-7027.
Maahs MA, Kiszewski AE, Rosa RF, Maria FD, Prates FB, Zen PR. Cephalometric skeletal evaluation of patients with incontinentia pigmenti. J Oral Biol Craniofac Res 2014; 4: 88-93.
Onnis G, Diociaiuti A, Zangari P et al. Cardiopulmonary anomalies in incontinentia pigmenti patients. Int J Dermatol 2018; 57: 40-45.
Atallah V, Meot M, Kossorotoff M et al. A case of reversible pulmonary arterial hypertension associated with incontinentia pigmenti. Pulm Circ 2018; 8: 2045894018793983.
Scheuerle AE. Incontinentia pigmenti in adults. Am J Med Genet A 2019; 179: 1415-1419.
Minic S, Trpinac D, Gabriel H, Gencik M, Obradovic M. Dental and oral anomalies in incontinentia pigmenti: a systematic review. Clin Oral Investig 2013; 17: 1-8.
Santa-Maria FD, Mariath LM, Poziomczyk CS et al. Dental anomalies in 14 patients with IP: clinical and radiological analysis and review. Clin Oral Investig 2017; 21: 1845-1852.
Chen AY, Chen K. Dental treatment considerations for a pediatric patient with incontinentia pigmenti (Bloch-Sulzberger syndrome). Eur J Dent 2017; 11: 264-267.
Mariath LM, Santa Maria FD, Poziomczyk CS et al. Intrafamilial clinical variability in four families with incontinentia pigmenti. Am J Med Genet A 2018; 176: 2318-2324.
Bardaro T, Falco G, Sparago A et al. Two cases of misinterpretation of molecular results in incontinentia pigmenti, and a PCR-based method to discriminate NEMO/IKKgamma dene deletion. Hum Mutat 2003; 21: 8-11.
Fusco F, Bardaro T, Fimiani G et al. Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappaB activation. Hum Mol Genet 2004; 13: 1763-1773.
Fusco F, Pescatore A, Bal E et al. Alterations of the IKBKG locus and diseases: an update and a report of 13 novel mutations. Hum Mutat 2008; 29: 595-604.
Fusco F, Paciolla M, Napolitano F et al. Genomic architecture at the incontinentia pigmenti locus favours de novo pathological alleles through different mechanisms. Hum Mol Genet 2012; 21: 1260-1271.
Fusco F, Pescatore A, Steffann J et al. Clinical utility gene card for: incontinentia pigmenti. Eur J Hum Genet 2013; 21: 792-792.
Conte MI, Pescatore A, Paciolla M et al. Insight into IKBKG/NEMO locus: report of new mutations and complex genomic rearrangements leading to incontinentia pigmenti disease. Hum Mutat 2014; 35: 165-177.
Steffann J, Raclin V, Smahi A et al. A novel PCR approach for prenatal detection of the common NEMO rearrangement in incontinentia pigmenti. Prenat Diagn 2004; 24: 384-388.
Alabdullatif Z, Coulombe J, Steffann J, Bodemer C, Hadj-Rabia S. Postzygotic mosaicism and incontinentia pigmenti in male patients: molecular diagnosis yield. Br J Dermatol 2018; 178: e261-e262.
Mullan E, Barbarian M, Trakadis Y, Moroz B. Incontinentia pigmenti in an XYboy: case report and review of the literature. J Cutan Med Surg 2014; 18: 119-122.
Hull S, Arno G, Thomson P et al. Somatic mosaicism of a novel IKBKG mutation in a male patient with incontinentia pigmenti. Am J Med Genet A 2015; 167: 1601-1604.
Fusco F, Conte MI, Diociaiuti A et al. Unusual father-to-daughter transmission of incontinentia pigmenti due to mosaicism in IP males. Pediatrics 2017; 140: 2016-2950.
Bal E, Laplantine E, Hamel Y et al. Lack of interaction between NEMO and SHARPIN impairs linear ubiquitination and NF-κB activation and leads to incontinentia pigmenti. J Allergy Clin Immunol 2017; 140: 1671-1682.e2.
Gigarel N, Frydman N, Burlet P et al. Single cell co-amplification of polymorphic markers for the indirect preimplantation genetic diagnosis of hemophilia A, X-linked adrenoleukodystrophy, X-linked hydrocephalus and incontinentia pigmenti loci on Xq28. Hum Genet 2004; 114: 298-305.
Morice-Picard FL, Leauté-Labrèze C. Incontinentia pigmenti. Thérapeutique Dermatol [Internet] 2013. URL https://www.therapeutique-dermatologique.org/spip.php?article1592&lang=en (last accessed: 23 October 2013).
Ehrenreich M, Tarlow MM, Godlewska-Janusz E Schwartz RA. Incontinentia pigmenti (Bloch-Sulzberger syndrome): a systemic disorder. Cutis 2007; 79: 355-362.
Kaya TI, Tursen U, Ikizoglu G. Therapeutic use of topical corticosteroids in the vesiculobullous lesions of incontinentia pigmenti. Clin Exp Dermatol 2009; 34: e611-e613.
Jessup CJ, Morgan SC, Cohen LM, Viders DE. Incontinentia pigmenti: treatment of IP with topical tacrolimus. J Drugs Dermatol 2009; 8: 944-946.
Nagase T, Takanashi M, Takada H, Ohmori K. Extensive vesiculobullous eruption following limited ruby laser treatment for incontinentia pigmenti: a case report. Australas J Dermatol 1997; 38: 155-157.
Malvehy J, Palou J, Mascaro JM. Painful subungual tumour in incontinentia pigmenti. Response to treatment with etretinate. Br J Dermatol 1998; 138: 554-555.
Donati P, Muscardin L, Amantea A, Paolini F. Venuti a detection of HPV-15 in painful subungual tumors of incontinentia pigmenti: successful topical therapy with retinoic acid. Eur J Dermatol 2009; 19: 243-247.
Escudero J, Borras F Fernandez MA, Dominguez C. [Fluorescein angiography with Retcam in incontinentia pigmenti: a case report]. Arch Soc Esp Oftalmol 2009; 84: 529-532.
Batioglu F, Ozmert E. Early indirect laser photocoagulation to induce regression of retinal vascular abnormalities in incontinentia pigmenti. Acta Ophthalmol 2010; 88: 267-268.
Ranchod TM, Trese MT. Regression of retinal neovascularization after laser photocoagulation in incontinentia pigmenti. Retina 2010; 30: 708-709.
Balaratnasingam C, Lam GC. Retinal sequelae of incontinentia pigmenti. Pediatr Int 2009; 51: 141-143.
DeVetten G, Ells A. Fluorescein angiographic findings in a male infant with incontinentia pigmenti. J AAPOS 2007; 11: 511-512.
Nguyen JK, Brady-Mccreery KM. Laser photocoagulation in preproliferative retinopathy of incontinentia pigmenti. J AAPOS 2001; 5: 258-259.
Dangouloff-Ros V, Hadj-Rabia S, Oliveira Santos J et al. Severe neuroimaging anomalies are usually associated with random X inactivation in leucocytes circulating DNA in X-linked dominant incontinentia pigmenti. Mol Genet Metab 2017; 122: 140-144.
Wolf DS, Golden WC, Hoover-Fong J et al. High-dose glucocorticoid therapy in the management of seizures in neonatal incontinentia pigmenti: a case report. J Child Neurol 2015; 30: 100-106.
Tomotaki S, Shibasaki J, Yunoki Y et al. Effectiveness of corticosteroid therapy for acute neurological symptoms in incontinentia pigmenti. Pediatr Neurol 2016; 56: 55-58.
Greene-Roethke C. Incontinentia pigmenti: a summary review of this rare ectodermal dysplasia with neurologic manifestations, including treatment protocols. J Pediatr Health Care 2017; 31: e45-e52.
Korbelin J, Dogbevia G, Michelfelder S et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol Med 2016; 8: 609-625.
Dominguez-Reyes A, Aznar-Martin T, Cabrera-Suarea E. General and dental characteristics of Bloch-Sulzberger syndrome. Review of literature and presentation of a case report. Med Oral 2002; 7: 293-297.